ARTICLE | Management Tracks
Sanofi’s Sarchi heads to Replimune
Plus: Albers joins Atlas, new CBO at Altimmune and updates from Nuvig, Zymeworks, Fulcrum, Step, Charm, Kymera and more
January 5, 2023 12:46 AM UTC
Replimune Group Inc. (NASDAQ:REPL) ramped up preparations for the launch of herpes-based oncolytic virus RP1 with the hiring of Chris Sarchi as chief commercial officer (CCO). Sarchi led the launch of Libtayo cemiplimab-rwlc as U.S. commercial oncology head at Sanofi (Euronext:SAN; NASDAQ:SNY), having also worked at Boehringer Ingelheim GmbH and Roche (SIX:ROG; OTCQX:RHHBY). He succeeds CCO Sushil Patel, who will take on the newly created role of chief strategy officer.
Jeff Albers joined Atlas Venture as venture partner. Albers was CEO at Blueprint Medicines Corp. (NASDAQ:BPMC) for eight years, before becoming executive chairman...